Moderate

Paraproteinaemia / monoclonal protein work-up

paraprotein w/u · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Detection of a monoclonal immunoglobulin requires determining whether it represents benign MGUS or an underlying plasma cell or lymphoproliferative malignancy, and whether the paraprotein itself is causing organ damage.

Red flags

  • CRAB features (hypercalcaemia, renal impairment, anaemia, bone lesions)
  • Nephrotic-range proteinuria or cardiac failure (amyloid)
  • Hyperviscosity (IgM paraprotein)
  • Rapidly rising paraprotein
  • Peripheral neuropathy with paraprotein

Assessment

Differential diagnosis

  • MGUS
  • Multiple myeloma
  • Waldenstrom macroglobulinaemia
  • AL amyloidosis
  • Smouldering myeloma
  • Lymphoma / CLL-associated paraprotein

Investigations

  • Serum protein electrophoresis and immunofixation; paraprotein quantification
  • Serum free light chains and ratio
  • FBC, calcium, renal function, albumin
  • Beta-2 microglobulin and immunoglobulin levels (immunoparesis)
  • Urine for Bence Jones protein
  • Skeletal imaging (low-dose CT/MRI) and marrow if myeloma suspected

Management

  • Characterise the paraprotein type and concentration
  • Assess for end-organ damage: the CRAB features (calcium, renal, anaemia, bone)
  • Quantify free light chains and look for immunoparesis
  • Stratify risk by paraprotein size, isotype (non-IgG higher risk) and light chain ratio
  • Diagnose MGUS when criteria met without myeloma-defining events
  • Investigate further (marrow, imaging) when risk factors or organ damage present
  • Consider amyloidosis if proteinuria, cardiac or neuropathic features
  • Consider Waldenstrom/lymphoma for IgM paraproteins with lymphoproliferative features
  • Set a surveillance schedule for MGUS based on risk category
  • Refer to haematology for high-risk, symptomatic or progressive disease

Drugs & doses

No treatment for asymptomatic MGUS - surveillance only
Treat underlying malignancy if diagnosed (see myeloma/lymphoma protocols)
Bone protection and supportive care if myeloma confirmed

Disposition

Primary care/haematology surveillance for low-risk MGUS; haematology referral for high-risk or symptomatic paraproteinaemia.

Complications & pitfalls

  • Progression of MGUS to myeloma/lymphoma
  • AL amyloidosis
  • Renal impairment (light chain / cast nephropathy)
  • Hyperviscosity syndrome
  • Pathological fractures if malignant

Exam pearls

  • MGUS carries roughly 1% annual progression risk - lifelong surveillance
  • Non-IgG isotype, high paraprotein and abnormal light chain ratio raise progression risk
  • IgM paraproteins point toward Waldenstrom/lymphoma, not myeloma
  • Suspect amyloidosis with proteinuria, cardiomyopathy or neuropathy
  • Free light chains are key for both diagnosis and monitoring

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.